Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

5.75
+0.04000.70%
Post-market: 5.750.00000.00%18:43 EDT
Volume:437.05K
Turnover:2.49M
Market Cap:409.11M
PE:-7.21
High:5.79
Open:5.67
Low:5.58
Close:5.71
52wk High:5.79
52wk Low:0.7101
Shares:71.15M
Float Shares:34.91M
Volume Ratio:0.64
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7970
EPS(LYR):-0.8000
ROE:-242.41%
ROA:-55.39%
PB:26.66
PE(LYR):-7.19

Loading ...

Company Profile

Company Name:
OPUS GENETICS INC
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
28
Office Location:
8 Davis Drive,Suite 220,Durham,North Carolina,United States
Zip Code:
27713
Fax:
- -
Introduction:
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Directors

Name
Position
Cam Gallagher
Independent Chairman of the Board
George Magrath
Chief Executive Officer and Director
Adrienne Graves
Independent Director
Benjamin R. Yerxa
Director and President
James S. Manuso
Independent Director
Jean Bennett
Independent Director
Richard Rodgers
Independent Director
Sean Ainsworth
Independent Director
Susan K. Benton
Independent Director

Shareholders

Name
Position
George Magrath
Chief Executive Officer and Director
Joseph Schachle
Chief Operating Officer
Robert Gagnon
Chief Financial Officer
Amy Rabourn
Head of Financial Quality Assurance
Ashwath Jayagopal
Chief Scientific and Development Officer
Benjamin R. Yerxa
Director and President